The PPARγ-mediated adjustment of the balance of glycolipid metabolism and the improvement in insulin resistance may be key measures for the prevention and treatment of NAFLD with celastrol. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.